Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. The company has proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and nucleic acid-based therapeutics.

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics is a global late stage-clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

Biomedical Advanced Research and Development Authority (BARDA)

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update 
and Pipeline Progress.

https://lnkd.in/eAgf78gv

#nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTCD #CF #ClinicalTrial #RareDiseases #Innovation #FinancialResults #Arcturus #ARCT $ARCT


We are delighted to announce that Arcturus Therapeutics was named on Deloitte's list of North America's most innovative, fastest-growing companies.
https://lnkd.in/ev8PTq8

#Fast500 #nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTC #CF #RareDiseases #Innovation #ARCT #Arcturus $ARCT

Dr. Igor Smolenov, Arcturus Therapeutics' Chief Development Officer is presenting at the 11ᵗʰ International mRNA Health Conference on Wednesday, November 1, 2023.
#Coronavirus #Vaccine #mRNA #RareDisease #ClinicalTrial #NextGenmRNA #mRNAhealthconference #mRNAconference #saRNA #mRNA2023 #Innovation #Arcturus $ARCT

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023. 
#nextgenerationmRNA #Covid19 #Vaccine #mRNA #OTC #CF #ClinicalTrial #RareDiseases #Innovation #FinancialResults #ARCT $ARCT



Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences. $ARCT

COM:ARCTURUSRX

Arcturus Therapeutics

Last Close

17.07

22/11 21:00

Market Cap

585.23M

Beta: -

Volume Today

512.97K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

investor of

competitor of

Metrics